These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3380052)

  • 21. Ocular changes in patients undergoing long-term desferrioxamine treatment.
    Arden GB; Wonke B; Kennedy C; Huehns ER
    Br J Ophthalmol; 1984 Dec; 68(12):873-7. PubMed ID: 6509007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity.
    Porter JB; Faherty A; Stallibrass L; Brookman L; Hassan I; Howes C
    Ann N Y Acad Sci; 1998 Jun; 850():483-7. PubMed ID: 9668591
    [No Abstract]   [Full Text] [Related]  

  • 23. [Auditory, visual and neurologic toxicity of deferoxamine].
    Caballero LG
    Rev Med Chil; 1989 May; 117(5):557-61. PubMed ID: 2519168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marrow proliferation as a cause of hearing loss in beta-thalassaemia major.
    Thio D; Prasad V; Anslow P; Lennox P
    J Laryngol Otol; 2008 Nov; 122(11):1253-6. PubMed ID: 17931455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allergy to desferrioxamine.
    Romeo MA; Di Gregorio F; Schiliro G
    J Inherit Metab Dis; 1984; 7(3):121. PubMed ID: 6438394
    [No Abstract]   [Full Text] [Related]  

  • 26. Yersinia pseudotuberculosis septicaemia in thalassaemia major.
    Gordts B; Rummens E; deMeirleir L; Butzler JP
    Lancet; 1984 Jan; 1(8367):41-2. PubMed ID: 6140358
    [No Abstract]   [Full Text] [Related]  

  • 27. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G; Koussi A; Economou M; Tsatra I; Perifanis V; Noussios G; Athanassiou-Metaxa M
    Acta Otorhinolaryngol Belg; 2004; 58(2):113-7. PubMed ID: 15515654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients.
    Chen SH; Liang DC; Lin HC; Cheng SY; Chen LJ; Liu HC
    J Pediatr Hematol Oncol; 2005 Dec; 27(12):651-3. PubMed ID: 16344669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Desferrioxamine in acute iron poisoning.
    Chan KW; Bond M; Fernandez W
    Lancet; 1992 Jun; 339(8809):1601-2. PubMed ID: 1351566
    [No Abstract]   [Full Text] [Related]  

  • 30. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.
    De Virgiliis S; Congia M; Turco MP; Frau F; Dessi C; Argiolu F; Sorcinelli R; Sitzia A; Cao A
    Arch Dis Child; 1988 Mar; 63(3):250-5. PubMed ID: 3355204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine.
    Cases A; Kelly J; Sabater J; Campistol JM; Torras A; Montoliu J; López I; Revert L
    Clin Nephrol; 1988 Apr; 29(4):176-8. PubMed ID: 3365862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid recovery with oral zinc sulphate in deferoxamine-induced presumed optic neuropathy and hearing loss.
    Pinna A; Corda L; Carta F
    J Neuroophthalmol; 2001 Mar; 21(1):32-3. PubMed ID: 11315979
    [No Abstract]   [Full Text] [Related]  

  • 33. Prophylaxis of systemic yersinosis in thalassaemia major.
    Scharnetzky M; König R; Lakomek M; Tillmann W; Schröter W
    Lancet; 1984 Apr; 1(8380):791. PubMed ID: 6143103
    [No Abstract]   [Full Text] [Related]  

  • 34. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
    Chiodo AA; Alberti PW; Sher GD; Francombe WH; Tyler B
    J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival and desferrioxamine in thalassaemia major.
    Modell B; Letsky EA; Flynn DM; Peto R; Weatherall DJ
    Br Med J (Clin Res Ed); 1982 Apr; 284(6322):1081-4. PubMed ID: 6802413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudo deep-vein thrombosis following desferrioxamine infusion: a previously unreported adverse reaction?
    Jacobs P; Wood L; Bird AR; Ultmann JE
    Lancet; 1990 Sep; 336(8718):815. PubMed ID: 1976177
    [No Abstract]   [Full Text] [Related]  

  • 37. Visual loss in patient on high-dose subcutaneous desferrioxamine.
    Borgna-Pignatti C; De Stefano P; Broglia AM
    Lancet; 1984 Mar; 1(8378):681. PubMed ID: 6142370
    [No Abstract]   [Full Text] [Related]  

  • 38. Survival and desferrioxamine in thalassaemia major.
    Murray JA
    Br Med J (Clin Res Ed); 1982 May; 284(6326):1401. PubMed ID: 6803993
    [No Abstract]   [Full Text] [Related]  

  • 39. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
    Cases A; Kelly J; Sabater F; Torras A; Griño MC; Lopez-Pedret J; Revert L
    Nephron; 1990; 56(1):19-23. PubMed ID: 2234245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment.
    Ambrosetti U; Dondè E; Piatti G; Cappellini MD
    Pharmacol Res; 2000 Nov; 42(5):485-7. PubMed ID: 11023713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.